Wang T.-S.TSEN-FANG TSAI2020-10-222020-10-2220130954-6634https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883582502&doi=10.3109%2f09546634.2012.672706&partnerID=40&md5=a39572c462ebd407d88dd63d7f356d1ehttps://scholars.lib.ntu.edu.tw/handle/123456789/517632Localized resistant plaques of psoriasis often remain despite highly effective anti-psoriasis treatment. Intralesional therapy is often used to treat various malignant, infectious or inflammatory cutaneous diseases, including psoriasis. Despite the presence of many review articles on the treatment of psoriasis, no articles exist which review the use of intralesional therapy for psoriasis. In this article, we review the published literatures of intralesional therapy for psoriasis. Corticosteroids, methotrexate, cyclosporin, biologics, botulinum toxin type-A, 15-hydroxyeicosatetraenoic acid, and chemotherapy agents such as 5-fluorouracil are discussed. Also, agents which may be used intralesionally and have the potential to treat psoriasis will also be reviewed such as bleomycin, vincristine or vinblastine, mitomycin-C, aminophylline, 5-aminolevulinic acid, rituximab, bevacizumab and pentoxifylline are included. ? 2013 Informa Healthcare USA on behalf of Informa UK Ltd.[SDGs]SDG315 hydroxyicosatetraenoic acid; adalimumab; alefacept; aminolevulinic acid; aminophylline; antiinflammatory agent; bevacizumab; bleomycin; botulinum toxin A; corticosteroid; cyclosporin; etanercept; etretin; fluorouracil; methotrexate; mitomycin; pentoxifylline; rituximab; vinblastine; vincristine; ankylosing arthritis; arthritis; chemotherapy; drug efficacy; drug megadose; drug potentiation; human; intralesional drug administration; low drug dose; nail psoriasis; priority journal; psoriasis; psoriatic arthritis; review; rheumatoid arthritis; treatment duration; Dermatologic Agents; Humans; Injections, Intralesional; Psoriasisreview10.3109/09546634.2012.672706223905392-s2.0-84883582502